Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients

Trial Profile

Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Liraglutide (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Lira-1
  • Most Recent Events

    • 13 Jun 2017 Results of effects of liraglutide-induced weight loss on BMD and bone turnover presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 10 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Results assessing cardiovascular effects of Liraglutide, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top